Beyond efficacy and safety: Economic Insights from our Large Clinical Trials

Tuesday, 26 May 2026, 1pm to 2pm

Bio:
Borislava's research programme focuses on economic aspects of chronic disease (such as cardiovascular, chronic kidney disease and diabetes) and comprises studies of the impact of disease events and interventions on morbidity, mortality, health-related quality of life and healthcare costs; development of disease models to evaluate long-term effects of disease and interventions, cost-effectiveness analyses of healthcare interventions and studies of socio-economic determinants of health.

She is leading/has led the development of the economic analyses in a number of large randomised controlled trials (EMPA-KIDNEY, ACST-2, REVEAL, SHARP, THRIVE) and in the individual participant data meta-analysis of statin trials (Cholesterol Treatment Collaboration).

Her work on effectiveness and cost-effectiveness of statins for cardiovascular disease prevention in the Heart Protection Study and the Cholesterol Treatment Collaboration has been influential in informing treatment recommendations for people at different vascular disease risk.

There will be tea/coffee and cake available in the atrium 30 min before the seminar.

Speaker(s): Professor Borislava Mihaylova (NDPH)

Series: Richard Doll Seminar

Venue: Richard Doll Building - Lecture Theatre - Lecture Theatre Richard Doll Building Old Road Campus Oxford Oxfordshire OX3 7LF United Kingdom

Department: Nuffield Department of Population Health (Department)

Organiser: Michelle Goonasekera

More info: